Skip to main content
. Author manuscript; available in PMC: 2016 Jul 28.
Published in final edited form as: Cancer Cell. 2015 Jun 25;28(1):42–56. doi: 10.1016/j.ccell.2015.05.007

Figure 4. SR9243 Reduces Tumor Growth, Glycolytic and Lipogenic Enzyme Expression in Tumors In Vivo.

Figure 4

(A) Volume of SW620 colon cancer xenografts in athymic mice treated with vehicle (n = 9), 30 mg/kg (n = 9), or 60 mg/kg (n = 9) SR9243.

(B) Total body weight of mice from (A).

(C and D) RT-PCR analysis of the (C) glycolytic genes GCK1, PFK1, and PFK2 and (D) the lipogenesis genes SREBP1c and SCD1 in tumors of mice treated with 30 and 60 mg/kg SR9243. RT-PCR data were analyzed using Student's t test. *p < 0.05.

(E) Immunoblot showing expression levels of SREBP1c, FASN, SCD1, GCK1, and PFK2 protein in SW620 tumors treated with 30 or 60 mg/kg SR9243.

(F) GC/MS determined concentration of pyruvate and glycerate in SW620 xenografts in mice treated with 30 mg/kg SR9243. Data were analyzed using Welch's t tests and/or Wilcoxon's rank sum tests. *p < 0.05. Error bars represent ±SEM.

(G) Oil red O staining showing lipid content of SW620 tumors in mice treated with 60 mg/kg SR9243 or vehicle.

(H) Fluorescence based in situ TUNEL assay showing apoptotic cells in tumors from mice treated with SR9243 (60 mg/kg) or vehicle control. See also Figure S4.